Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals gained 0.860% compared to yesterday.
The stock is one of the favorites of our community with 27 Buy predictions and 1 Sell predictions.
With a target price of 27 € there is a slightly positive potential of 17.7% for Acadia Pharmaceuticals compared to the current price of 22.94 €.
Our community identified positive and negative aspects for Acadia Pharmaceuticals stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Acadia Pharmaceuticals stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | 0.860% | 7.096% | 19.541% | 30.341% | 42.706% | 55.758% | -47.076% |
| Ironwood Pharmaceuticals | 0.000% | -3.797% | 84.242% | -12.644% | -27.619% | -72.543% | -69.293% |
| Novocure Ltd | 3.110% | 11.759% | 16.191% | -59.936% | -61.161% | -84.188% | -91.887% |
| Iovance Biotherapeutics Inc. | 0.710% | 2.465% | -5.304% | -76.280% | -71.952% | -70.459% | -95.240% |
Comments
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $33.00 to $31.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at Royal Bank Of Canada from $34.00 to $32.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat